{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:40:06Z","timestamp":1779111606729,"version":"3.51.4"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI175821"],"award-info":[{"award-number":["R21 AI175821"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI190338"],"award-info":[{"award-number":["R21 AI190338"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23 AI185174"],"award-info":[{"award-number":["K23 AI185174"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.amjms.2025.10.009","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:03:40Z","timestamp":1760997820000},"page":"140-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multidrug-resistant gram-negative organisms: A primer on mechanisms of resistance and emerging therapies for the non-infectious diseases clinician"],"prefix":"10.1016","volume":"371","author":[{"given":"R. Alfonso Hernandez","family":"Acosta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max W.","family":"Adelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse T.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1518-2973","authenticated-orcid":false,"given":"William R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0001","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jiph.2022.12.022","article-title":"Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review","volume":"16","author":"Abubakar","year":"2023","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.amjms.2025.10.009_bib0002","article-title":"Antimicrobial resistance threats in the United States, 2021-2022","year":"2024","journal-title":"Antimicrobial Resistance"},{"key":"10.1016\/j.amjms.2025.10.009_bib0003","unstructured":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections | Clinical Infectious Diseases | Oxford Academic. Accessed March 20, 2025. https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciae403\/7728556?login=true#506570725."},{"issue":"8","key":"10.1016\/j.amjms.2025.10.009_bib0004","doi-asserted-by":"crossref","first-page":"ofz353","DOI":"10.1093\/ofid\/ofz353","article-title":"Molecular epidemiology of ceftriaxone non-susceptible enterobacterales isolates in an academic medical center in the united states","volume":"6","author":"Tamma","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijantimicag.2018.09.012","article-title":"The intrinsic resistome of Klebsiella pneumoniae","volume":"53","author":"Bernardini","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0006","doi-asserted-by":"crossref","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","article-title":"Extended-spectrum \u03b2-lactamases: an update on their characteristics, epidemiology and detection","volume":"3","author":"Castanheira","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"s1","key":"10.1016\/j.amjms.2025.10.009_bib0007","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1469-0691.2007.01846.x","article-title":"Phenotypic detection of extended-spectrum \u03b2-lactamase production in Enterobacteriaceae: review and bench guide","volume":"14","author":"Drieux","year":"2008","journal-title":"Clin Microbiol Infection"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0008","doi-asserted-by":"crossref","first-page":"dlab020","DOI":"10.1093\/jacamr\/dlab020","article-title":"CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales","volume":"3","author":"Mathers","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.009_bib0009","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin\/Tazobactam or Meropenem From the MERINO Study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.009_bib0010","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.009_bib0011","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjms.2025.10.009_bib0012","unstructured":"Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial | Infectious Diseases | JAMA | JAMA Network. Accessed March 18, 2025. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2702145."},{"issue":"5","key":"10.1016\/j.amjms.2025.10.009_bib0013","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ijantimicag.2008.10.005","article-title":"Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis","volume":"33","author":"Brink","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.009_bib0014","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1093\/jac\/dku226","article-title":"Unbound fraction of ertapenem in intensive care unit patients","volume":"69","author":"Liebchen","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cmi.2024.09.031","article-title":"In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives","volume":"31","author":"Bonnin","year":"2025","journal-title":"Clin Microbiol Infection"},{"issue":"13","key":"10.1016\/j.amjms.2025.10.009_bib0016","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.009_bib0017","doi-asserted-by":"crossref","first-page":"e00313","DOI":"10.1128\/AAC.00313-18","article-title":"In Vitro activity of plazomicin against gram-negative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant enterobacteriaceae and isolates carrying carbapenemase genes","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.009_bib0018","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-Daily Plazomicin for Complicated Urinary Tract Infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0019","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.009_bib0020","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for Injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, A Phase 2\/3 Randomized Trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of fosfomycin for the treatment of multidrug-resistant escherichia coli bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38691","article-title":"The role of intravenous fosfomycin: finding our way out of dante\u2019s forest dark","volume":"5","author":"Tamma","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.009_bib0023","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/jac\/dkad099","article-title":"In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program","volume":"78","author":"Maher","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem or ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: A Phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cid\/ciac704","article-title":"Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: a Phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.009_bib0026","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/00365540110080728","article-title":"Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women","volume":"34","author":"Nicolle","year":"2002","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0027","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0924-8579(99)00118-1","article-title":"Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection","volume":"13","author":"Menday","year":"2000","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.009_bib0028","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 Update by the infectious diseases society of america and the european society for microbiology and infectious diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Diseases"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0029","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/jac\/dkac396","article-title":"Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption","volume":"78","author":"Frimodt-M\u00f8ller","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01492-21","article-title":"Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections","volume":"66","author":"Scangarella-Oman","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0031","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjms.2025.10.009_bib0032","unstructured":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials - The Lancet. Accessed April 7, 2025. https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(23)02196-7\/abstract."},{"issue":"8","key":"10.1016\/j.amjms.2025.10.009_bib0033","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"Antibacterial Resistance Leadership Group. A Primer on ampc \u03b2-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"s1","key":"10.1016\/j.amjms.2025.10.009_bib0034","doi-asserted-by":"crossref","first-page":"s87","DOI":"10.1111\/j.1469-0691.1997.tb00649.x","article-title":"Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility","volume":"3","author":"Garau","year":"1997","journal-title":"Clin Microbiol Inf"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0035","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkv346","article-title":"Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis","volume":"71","author":"Harris","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.009_bib0036","doi-asserted-by":"crossref","first-page":"ofz248","DOI":"10.1093\/ofid\/ofz248","article-title":"Beta-lactam\/beta-lactamase inhibitor therapy for potential ampc-producing organisms: a systematic review and meta-analysis","volume":"6","author":"Cheng","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.009_bib0037","doi-asserted-by":"crossref","first-page":"ofab387","DOI":"10.1093\/ofid\/ofab387","volume":"8","author":"Stewart","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.009_bib0038","doi-asserted-by":"crossref","first-page":"ofad175","DOI":"10.1093\/ofid\/ofad175","article-title":"The frequency of extended-spectrum \u03b2-lactamase genes harbored by enterobacterales isolates at high risk for clinically significant chromosomal ampC expression","volume":"10","author":"Hareza","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.009_bib0039","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1128\/AAC.01477-15","article-title":"Cefepime therapy for monomicrobial enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.009_bib0040","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jac\/dky084","article-title":"Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC \u03b2-lactamase","volume":"73","author":"Kohlmann","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0041","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12941-023-00624-9","article-title":"Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales","volume":"22","author":"\u00c1vila-N\u00fa\u00f1ez","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.009_bib0042","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00476-22","article-title":"Systematic analysis of mobile genetic elements mediating \u03b2-Lactamase gene amplification in noncarbapenemase-producing carbapenem-resistant enterobacterales bloodstream infections","volume":"7","author":"Shropshire","year":"2022","journal-title":"mSystems"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0043","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjms.2025.10.009_bib0044","series-title":"StatPearls","article-title":"Carbapenem-Resistant Enterobacterales","author":"Smith","year":"2025"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0045","doi-asserted-by":"crossref","first-page":"ofad046","DOI":"10.1093\/ofid\/ofad046","article-title":"Changing epidemiology of carbapenemases among carbapenem-resistant enterobacterales from united states hospitals and the activity of aztreonam-avibactam against contemporary enterobacterales (2019\u20132021)","volume":"10","author":"Sader","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.009_bib0046","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3390\/medicina58111675","article-title":"An overview on phenotypic and genotypic characterisation of carbapenem-resistant enterobacterales","volume":"58","author":"Rabaan","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.009_bib0047","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00397-20","article-title":"Metallo-\u03b2-lactamases: structure, function, epidemiology, treatment options, and the development pipeline","volume":"64","author":"Boyd","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.009_bib0048","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/jac\/dks121","article-title":"OXA-48-like carbapenemases: the phantom menace","volume":"67","author":"Poirel","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.009_bib0049","doi-asserted-by":"crossref","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.amjms.2025.10.009_bib0050","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.009_bib0051","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02171-20","article-title":"New perspectives on antimicrobial agents: cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.009_bib0052","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/phar.4629","article-title":"Aztreonam-avibactam: the dynamic duo against multidrug-resistant gram-negative pathogens","volume":"44","author":"Al Musawa","year":"2024","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0053","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijantimicag.2016.10.013","article-title":"Susceptibility to cephalosporin combinations and aztreonam\/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission","volume":"49","author":"Mischnik","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.009_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01647-22","article-title":"Multicenter evaluation of an MIC-based aztreonam and ceftazidime-avibactam broth disk elution test","volume":"61","author":"Harris","year":"2023","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.009_bib0055","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.009_bib0056","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/jac\/dkad004","article-title":"Rapid selection of a cefiderocol-resistant Escherichia coli producing NDM-5 associated with a single amino acid substitution in the CirA siderophore receptor","volume":"78","author":"Jousset","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.009_bib0057","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00311-22","article-title":"NDM-35-producing ST167 escherichia coli highly resistant to \u03b2-lactams including cefiderocol","volume":"66","author":"Poirel","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0058","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02670-21","article-title":"Occurrence of high levels of cefiderocol resistance in carbapenem-resistant escherichia coli before its approval in china: a report from China CRE-Network","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"7","key":"10.1016\/j.amjms.2025.10.009_bib0059","doi-asserted-by":"crossref","first-page":"ofad276","DOI":"10.1093\/ofid\/ofad276","article-title":"An NDM-producing escherichia coli clinical isolate exhibiting resistance to cefiderocol and the combination of ceftazidime-avibactam and aztreonam: another step toward Pan-\u03b2-Lactam resistance","volume":"10","author":"Simner","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0060","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jac\/dkac425","article-title":"Phenotypes, genotypes and breakpoints: an assessment of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against OXA-48","volume":"78","author":"Asempa","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.amjms.2025.10.009_bib0061","first-page":"1173","article-title":"Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae","volume":"41","author":"Lima","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.009_bib0062","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01100-22","article-title":"Evidence for efficacy of cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials","volume":"66","author":"Longshaw","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.009_bib0063","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0064","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.amjms.2025.10.009_bib0065","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2147\/IDR.S396910","article-title":"Antibacterial activity of eravacycline against carbapenem-resistant gram-negative isolates in china: an in vitro study","volume":"16","author":"Zou","year":"2023","journal-title":"Infect Drug Resist"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.009_bib0066","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02488-19","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the united states and europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjms.2025.10.009_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2021.05.079","article-title":"Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia","volume":"109","author":"Hakeam","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0068","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.009_bib0069","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.amjms.2025.10.009_bib0070","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.009_bib0071","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01677-23","article-title":"Daily fosfomycin versus levofloxacin for complicated urinary tract infections","volume":"14","author":"Rouphael","year":"2023","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.009_bib0072","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1093\/jac\/dkac233","article-title":"Antimicrobial activity of cefepime\/zidebactam (WCK 5222), a \u03b2-lactam\/\u03b2-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19)","volume":"77","author":"Sader","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0073","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01510-23","article-title":"The metallo-\u03b2-lactamases strike back: emergence of taniborbactam escape variants","volume":"68","author":"Tamma","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0074","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01281-22","article-title":"In vitro activity of cefepime-taniborbactam and comparators against clinical isolates of gram-negative bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (GEARS) Program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjms.2025.10.009_bib0075","unstructured":"Cefepime\u2013Taniborbactam in Complicated Urinary Tract Infection | New England Journal of Medicine. Accessed March 20, 2025. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2304748."},{"key":"10.1016\/j.amjms.2025.10.009_bib0076","unstructured":"Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae | New England Journal of Medicine. Accessed March 20, 2025. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc1807634."},{"issue":"6","key":"10.1016\/j.amjms.2025.10.009_bib0077","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/antibiotics10060672","article-title":"Advances in bacteriophage therapy against relevant MultiDrug-resistant pathogens","volume":"10","author":"Broncano-Lavado","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"9","key":"10.1016\/j.amjms.2025.10.009_bib0078","doi-asserted-by":"crossref","first-page":"ofaa389","DOI":"10.1093\/ofid\/ofaa389","article-title":"Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States","volume":"7","author":"Aslam","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.amjms.2025.10.009_bib0079","unstructured":"Function of Pseudomonas Porins in Uptake and Efflux | Annual Reviews. Accessed March 20, 2025. https:\/\/www.annualreviews.org\/content\/journals\/10.1146\/annurev.micro.56.012302.160310."},{"issue":"12","key":"10.1016\/j.amjms.2025.10.009_bib0080","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2165\/11317030-000000000-00000","article-title":"Efflux-mediated drug resistance in bacteria: an update","volume":"69","author":"Li","year":"2009","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0081","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3947\/ic.2015.47.2.81","article-title":"Epidemiology and characteristics of metallo-\u03b2-lactamase-producing pseudomonas aeruginosa","volume":"47","author":"Hong","year":"2015","journal-title":"Infect Chemother"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0082","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol Adv"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.009_bib0083","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"0","key":"10.1016\/j.amjms.2025.10.009_bib0084","article-title":"Effectiveness of ceftazidime\u2013avibactam versus ceftolozane\u2013tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study","volume":"0","author":"Shields","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.009_bib0085","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0086","doi-asserted-by":"crossref","first-page":"dlad152","DOI":"10.1093\/jacamr\/dlad152","article-title":"Activity of ceftolozane\/tazobactam, imipenem\/relebactam and ceftazidime\/avibactam against clinical Gram-negative isolates-SMART United States 2019-21","volume":"6","author":"Karlowsky","year":"2024","journal-title":"JAC Antimicrob Resist"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.009_bib0087","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00084-21","article-title":"In vitro susceptibility of multidrug-resistant pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam","volume":"65","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.amjms.2025.10.009_bib0088","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"10.1016\/j.amjms.2025.10.009_bib0089","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01009-23","article-title":"The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy","volume":"68","author":"Teran","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0090","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.amjms.2025.10.009_bib0091","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00500-23","article-title":"Successful Use of Cefepime-Zidebactam (WCK 5222) as a salvage therapy for the treatment of disseminated extensively drug-resistant new delhi metallo-\u03b2-lactamase-producing pseudomonas aeruginosa infection in an adult patient with acute T-cell leukemia","author":"Tirlangi","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"21","key":"10.1016\/j.amjms.2025.10.009_bib0092","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1073\/pnas.1800961115","article-title":"Structural basis for Acinetobacter baumannii biofilm formation","volume":"115","author":"Pakharukova","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0093","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/pathogens10030373","article-title":"Acinetobacter baumannii antibiotic resistance mechanisms","volume":"10","author":"Kyriakidis","year":"2021","journal-title":"Pathogens"},{"issue":"11","key":"10.1016\/j.amjms.2025.10.009_bib0094","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1128\/AAC.00427-10","article-title":"Genetic and functional variability of AmpC-type \u03b2-lactamases from Acinetobacter baumannii","volume":"54","author":"Rodr\u00edguez-Mart\u00ednez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/antibiotics3030398","article-title":"Acquired Class D \u03b2-Lactamases","volume":"3","author":"Antunes","year":"2014","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.amjms.2025.10.009_bib0096","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01268-16","article-title":"High-dose ampicillin-sulbactam combinations combat polymyxin-resistant acinetobacter baumannii in a hollow-fiber infection model","volume":"61","author":"Lenhard","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.amjms.2025.10.009_bib0097","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1093\/cid\/ciad095","article-title":"Durlobactam, a broad-spectrum serine \u03b2-lactamase inhibitor, restores sulbactam activity against acinetobacter species","volume":"76","author":"Papp-Wallace","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0098","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/cid\/ciad556","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant acinetobacter baumannii among patients from different global regions","volume":"78","author":"Wang","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.009_bib0099","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1469-0691.2004.00987.x","article-title":"Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii","volume":"10","author":"Choi","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.amjms.2025.10.009_bib0100","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01627-24","article-title":"A microbiological and structural analysis of the interplay between sulbactam\/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp","volume":"69","author":"Veeraraghavan","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.amjms.2025.10.009_bib0101","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.amjms.2025.10.009_bib0102","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"Suppl 6","key":"10.1016\/j.amjms.2025.10.009_bib0103","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1093\/cid\/ciu594","article-title":"Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center","volume":"59","author":"Pogue","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.amjms.2025.10.009_bib0104","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.amjms.2025.10.009_bib0105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.amjms.2025.10.009_bib0106","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2666-5247(21)00271-8","article-title":"Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?","volume":"2","author":"Choby","year":"2021","journal-title":"Lancet Microbe"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.009_bib0107","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02371-23","article-title":"Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis","volume":"11","author":"Longshaw","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"6","key":"10.1016\/j.amjms.2025.10.009_bib0108","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","article-title":"Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-\u03b2-lactamase inhibitor for carbapenem-resistant bacterial infections","volume":"63","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.amjms.2025.10.009_bib0109","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1128\/AAC.00873-15","article-title":"Can Plazomicin alone or in combination be a therapeutic option against carbapenem-resistant acinetobacter baumannii?","volume":"59","author":"Garc\u00eda-Salguero","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925012467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925012467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:19:46Z","timestamp":1773274786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962925012467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0002962925012467"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2025.10.009","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidrug-resistant gram-negative organisms: A primer on mechanisms of resistance and emerging therapies for the non-infectious diseases clinician","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2025.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}